Functional characterization

Biologics and vaccine developers leverage our expertise in functional characterization to guide their product development, from discovery to application for clinical trials. We can help you identify targets and biomarkers, and select hits through high-throughput screening. We excel at evaluating the behaviour of complex protein therapeutics and vaccines – including binding, signaling, internalization, mechanism of action, toxicity, biodistribution, immunogenicity, immunostimulation, efficacy, and safety – in living cells and organisms.

Our assays and documentation support you as you prepare a Clinical Trial Application (CTA) in Canada or Investigational New Drug (IND) application in the USA, ensuring that results generated in the lab are translated to the benefit of patients. We also transfer our data and methods to Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs), enabling them to offer new services while strengthening the Canadian biopharma ecosystem.

R&D expertise

IN VITRO

IN VIVO

Contacts

Jean Labrecque
Team Leader, Primary Assays
Telephone: 514-496-5323
EmailJean.Labrecque@cnrc-nrc.gc.ca

Risini Weeratna
Team Leader, Cancer Immunology
Telephone: 613-990-7934
EmailRisini.Weeratna@nrc-cnrc.gc.ca

Martin Perkins
Section Head, Molecular Pharmacology
Telephone: 613-998-4018
EmailMartin.Perkins@nrc-cnrc.gc.ca

Maria Moreno
Section Head, In Vivo Pharmacology
Telephone: 613-990-0829
EmailMaria.Moreno@nrc-cnrc.gc.ca

Supplemental content

Case study

Soricimed Biopharma conducted its first in vivo proof-of-concept studies with NRC to demonstrate the ability of their Soricidin-derived (SOR) peptides to specifically target TRPV6 in ovarian and prostate tumors in mice. This key step validates Soricimed’s approach of using SOR peptides as tumor biomarkers and opens up the possibility of using them as homing agents to deliver anti-cancer agents.

Date modified: